No Data
No Data
China Grants Investigational New Drug Status to Qyuns Therapeutics' Urticaria Treatment
China's medical products administrator granted investigational new drug status to Qyuns Therapeutics' (HKG:2509) QX013N for chronic spontaneous urticaria, a skin condition, according to a Thursday fil
Quanxin Bio-B (02509.HK) obtained QX013N clinical trial approval for a new drug for the treatment of chronic spontaneous urticaria in China
Gelonghui, May 9, 丨 Quanxin Bio-B (02509.HK) announced that on May 9, 2024, the humanized IgG1 monoclonal antibody Qx013n independently developed by the company obtained a new drug clinical trial license (acceptance number: CXSL2400165) from the China National Drug Administration Drug Evaluation Center for the treatment of chronic spontaneous urticaria (CSU). Qx013n is China's first biopharmaceutical candidate targeting c-Kit. CSU is a common chronic inflammatory skin disease characterized by spontaneous skin lumps and/or angioedema, which lasts longer than
荃信生物-B:2023年度報告
[Monthly IPO Report] The Hong Kong stock IPO market is the starting force, Fujing China Holdings overbought more than 293 times, and Hongji Group made a maximum profit of 4,800 yuan in the first sale
After February's silence, the Hong Kong stock IPO market exploded in March. Seven companies went public one after another, and only 1 went bankrupt. Source: Jinwu Financial News March Fund-raising King - Although the number of listed companies has clearly picked up, it still lacks the boost of large companies. Judging from the scale of fund-raising, the 7 new shares introduced in March were small in overall size, and the Miko Group, which raised the highest amount of capital, was only HK$918 million. According to reports, the company is the third-largest potash enterprise in China and has market advantages. However, industry growth is expected to be in the low single digits. The market for the company's main product, potassium chloride, is also relatively concentrated, and development needs to face challenges. Sino-Thai International said earlier that the government
QYUNS-B: FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
Changes in Hong Kong stocks | Quanxin Bio-B (02509) rose by more than 14%. The company is deeply involved in the self-exempt circuit, and the QX001S is expected to become the first commercial product
The Zhitong Finance App learned that Quanxin Biotech B (02509) rose by more than 14%. As of press release, it had risen 12.06% to HK$20.35, with a turnover of HK$318.66. According to reports, Quanxin Biotech is a clinical-stage biotechnology company focusing on the development of biotherapies for autoimmune and allergic diseases. The company's core competitiveness is its two core products, QX002N and QX005N, which are independently developed. QX002N is an IL-17A inhibitor. The company has conducted phase III clinical trials for the treatment of ankylosing spondylitis (AS) in China. QX005N is a resistor
No Data